Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Trial Details

NCT ID

NCT04494503

Phase

PHASE1 / PHASE2

Sponsor

Ascentage Pharma Group Inc.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• APG-2575
• Rituximab
• Ibrutinib

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Chongqing, Chongqing Municipality, China|29.56026,106.55771
• Guangzhou, Guangdong, China|23.11667,113.25
• Nanning, Guangxi, China|22.81667,108.31667
• Guiyang, Guizhou, China|26.58333,106.71667

Key Eligibility Criteria

• Subjects who meet each of the following inclusion criteria are eligible to participate in this study:
• Age ≥18 years old.
• Diagnosis as relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma according to the IWCLL NCI-WG guidelines revised in 2008.
• Through radiological assessment, subjects with a lymph node length ≥ 10 cm require prior approval from the sponsor before enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.